Avenue Ev To Free Cash Flow from 2010 to 2025

ATXI Stock  USD 0.85  0.06  7.59%   
Avenue Therapeutics' EV To Free Cash Flow is increasing with slightly volatile movements from year to year. EV To Free Cash Flow is estimated to finish at 0.01 this year. EV To Free Cash Flow is a valuation metric comparing Avenue Therapeutics' enterprise value to its free cash flow, used to evaluate whether Avenue Therapeutics is undervalued or overvalued. View All Fundamentals
 
EV To Free Cash Flow  
First Reported
2010-12-31
Previous Quarter
0.005762
Current Value
0.006051
Quarterly Volatility
890.61408894
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Avenue Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Avenue Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 165.9 K, Depreciation And Amortization of 17.6 M or Interest Expense of 350.7 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.02. Avenue financial statements analysis is a perfect complement when working with Avenue Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Avenue Therapeutics Correlation against competitors.
For more detail on how to invest in Avenue Stock please use our How to Invest in Avenue Therapeutics guide.

Latest Avenue Therapeutics' Ev To Free Cash Flow Growth Pattern

Below is the plot of the Ev To Free Cash Flow of Avenue Therapeutics over the last few years. It is a valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued. Avenue Therapeutics' EV To Free Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Avenue Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Ev To Free Cash Flow10 Years Trend
Slightly volatile
   Ev To Free Cash Flow   
       Timeline  

Avenue Ev To Free Cash Flow Regression Statistics

Arithmetic Mean(867.32)
Coefficient Of Variation(102.69)
Mean Deviation710.68
Median(430.74)
Standard Deviation890.61
Sample Variance793,193
Range3.4K
R-Value0.62
Mean Square Error518,351
R-Squared0.39
Significance0.01
Slope116.83
Total Sum of Squares11.9M

Avenue Ev To Free Cash Flow History

2025 0.006051
2024 0.005762
2023 0.006403
2022 -24.14
2021 -307.67
2020 -1311.76
2019 -430.74

About Avenue Therapeutics Financial Statements

Investors use fundamental indicators, such as Avenue Therapeutics' Ev To Free Cash Flow, to determine how well the company is positioned to perform in the future. Although Avenue Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
EV To Free Cash Flow 0.01  0.01 

Currently Active Assets on Macroaxis

When determining whether Avenue Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Avenue Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Avenue Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Avenue Therapeutics Stock:
Check out the analysis of Avenue Therapeutics Correlation against competitors.
For more detail on how to invest in Avenue Stock please use our How to Invest in Avenue Therapeutics guide.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avenue Therapeutics. If investors know Avenue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avenue Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.76)
Earnings Share
24.78
Return On Assets
(4.72)
Return On Equity
(5.35)
The market value of Avenue Therapeutics is measured differently than its book value, which is the value of Avenue that is recorded on the company's balance sheet. Investors also form their own opinion of Avenue Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Avenue Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avenue Therapeutics' market value can be influenced by many factors that don't directly affect Avenue Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avenue Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avenue Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avenue Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.